cagrilintide novo nordisk Coadministered and Semaglutide in Adults with Overweight or Obesity Novo Nordisk's next-gen obesity drug – Novo's CagriSema stumbles against Lilly's

Particularly extensive literature in skin biology and wound healing contexts

Problem : Incomplete healing, injury returns

Both of those treatments are well-studied

14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type 2 Diabetes Mellitus Add-on to metformin SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly

These are access-pathway questions rather than therapeutic approval

Does it help with weight loss